• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bcl-2通过减少激活诱导的细胞凋亡增强嵌合抗原受体T细胞的持久性。

Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis.

作者信息

Wang Haiyong, Han Ping, Qi Xinyue, Li Fanlin, Li Min, Fan Lilv, Zhang Huihui, Zhang Xiaoqing, Yang Xuanming

机构信息

Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.

Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.

出版信息

Cancers (Basel). 2021 Jan 8;13(2):197. doi: 10.3390/cancers13020197.

DOI:10.3390/cancers13020197
PMID:33429845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7827522/
Abstract

PURPOSE

To evaluate the potential added value of integrating anti-apoptotic molecules for improving the anti-tumor activity of CAR-T cells.

METHODS

Four small molecules inhibiting apoptosis were tested for their ability to prevent activated induced CAR-T cell death. Five CD20-targeting, CD137 (4-1BB) and CD3ζ integrated CAR-T cells (20BBZ) with constitutively expressed anti-apoptotic genes were established, and we screened out the strongest proliferation enhancer: Bcl-2. The memory subtype and the exhaustion markers of CAR-T cells were analyzed. The anti-tumor activities of Bcl-2 integrating CAR-T cells (20BBZ-Bcl-2) were evaluated in vitro and in a mouse xenograft lymphoma model.

CONCLUSION

The 20BBZ-Bcl-2 CAR-T cells showed improved proliferation ability compared to 20BBZ CAR-T cells in vitro. In addition, activation-induced apoptosis was reduced in the 20BBZ-Bcl-2 CAR-T cells. Consistent with the enhanced proliferation in vitro, 20BBZ-Bcl-2 CAR-T cells exhibited improved anti-tumor activity in a mouse xenograft lymphoma model.

摘要

目的

评估整合抗凋亡分子对提高嵌合抗原受体T细胞（CAR-T细胞）抗肿瘤活性的潜在附加价值。

方法

测试了四种抑制凋亡的小分子阻止活化诱导的CAR-T细胞死亡的能力。构建了五个整合了靶向CD20、CD137（4-1BB）和CD3ζ且组成性表达抗凋亡基因的CAR-T细胞（20BBZ），并筛选出最强的增殖增强剂：Bcl-2。分析了CAR-T细胞的记忆亚型和耗竭标志物。在体外和小鼠异种移植淋巴瘤模型中评估了整合Bcl-2的CAR-T细胞（20BBZ-Bcl-2）的抗肿瘤活性。

结论

与20BBZ CAR-T细胞相比，20BBZ-Bcl-2 CAR-T细胞在体外显示出更强的增殖能力。此外，20BBZ-Bcl-2 CAR-T细胞中活化诱导的凋亡减少。与体外增殖增强一致，20BBZ-Bcl-2 CAR-T细胞在小鼠异种移植淋巴瘤模型中表现出更好的抗肿瘤活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/151270d0a989/cancers-13-00197-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/7e1e44666aae/cancers-13-00197-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/7f7e00269dfb/cancers-13-00197-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/60fa20f242cf/cancers-13-00197-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/dcfee8294f2a/cancers-13-00197-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/647d6e0e6fd9/cancers-13-00197-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/151270d0a989/cancers-13-00197-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/7e1e44666aae/cancers-13-00197-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/7f7e00269dfb/cancers-13-00197-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/60fa20f242cf/cancers-13-00197-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/dcfee8294f2a/cancers-13-00197-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/647d6e0e6fd9/cancers-13-00197-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d672/7827522/151270d0a989/cancers-13-00197-g006.jpg

相似文献

1
Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis.Bcl-2通过减少激活诱导的细胞凋亡增强嵌合抗原受体T细胞的持久性。
Cancers (Basel). 2021 Jan 8;13(2):197. doi: 10.3390/cancers13020197.
2
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
3
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.嵌合抗原受体信号的磷酸化蛋白质组学分析揭示了影响细胞功能的动力学和定量差异。
Sci Signal. 2018 Aug 21;11(544):eaat6753. doi: 10.1126/scisignal.aat6753.
4
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced Persistence and Antitumor Activity against Neuroblastoma.同时表达 GD2 特异性嵌合抗原受体和 IL15 的 NKT 细胞对神经母细胞瘤表现出增强的持久性和抗肿瘤活性。
Clin Cancer Res. 2019 Dec 1;25(23):7126-7138. doi: 10.1158/1078-0432.CCR-19-0421. Epub 2019 Sep 4.
5
Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.抗 GD2/4-1BB 嵌合抗原受体 T 细胞疗法治疗中国黑色素瘤患者。
J Hematol Oncol. 2018 Jan 3;11(1):1. doi: 10.1186/s13045-017-0548-2.
6
Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.抗 CD19 嵌合抗原受体 T 细胞对 B 细胞淋巴瘤的活性通过抗体靶向干扰素-α增强。
J Interferon Cytokine Res. 2018 Jun;38(6):239-254. doi: 10.1089/jir.2018.0030.
7
Approaches to augment CAR T-cell therapy by targeting the apoptotic machinery.通过靶向凋亡机制增强嵌合抗原受体（CAR）T细胞疗法的方法。
Biochem Soc Trans. 2016 Apr 15;44(2):371-6. doi: 10.1042/BST20150253.
8
Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.嵌合抗原受体工程 T（CAR-T）细胞和肿瘤特异性 T 细胞的生存时间延长是由抗程序性细胞死亡蛋白 1 单链可变片段产生的 CAR-T 细胞引起的。
Cancer Sci. 2019 Oct;110(10):3079-3088. doi: 10.1111/cas.14169. Epub 2019 Sep 17.
9
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.一种新型抗GD2/4-1BB嵌合抗原受体可触发神经母细胞瘤细胞杀伤。
Oncotarget. 2015 Sep 22;6(28):24884-94. doi: 10.18632/oncotarget.4670.
10
Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.肿瘤抗原和受体密度调节靶向间变性淋巴瘤激酶的嵌合抗原受体的疗效。
Mol Ther. 2017 Sep 6;25(9):2189-2201. doi: 10.1016/j.ymthe.2017.06.008. Epub 2017 Jul 1.

引用本文的文献

1
BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer.BCL-2突变型B7H6嵌合抗原受体T细胞（BCL-2 mutant B7H6-CAR-T cells）与维奈克拉协同作用治疗小细胞肺癌。
J Immunother Cancer. 2025 May 7;13(5):e010073. doi: 10.1136/jitc-2024-010073.
2
Enhancing the physiological characteristics of chimeric antigen receptor natural killer cells by synthetic biology.通过合成生物学增强嵌合抗原受体自然杀伤细胞的生理特性。
Front Immunol. 2025 Apr 17;16:1592121. doi: 10.3389/fimmu.2025.1592121. eCollection 2025.
3
Addressing the challenges of infectious bone defects: a review of recent advances in bifunctional biomaterials.

本文引用的文献

1
Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies.人源化小鼠是CAR-T和CAR-NK细胞疗法临床前评估的宝贵工具。
Cancers (Basel). 2020 Jul 15;12(7):1915. doi: 10.3390/cancers12071915.
2
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.分泌双特异性 T 细胞衔接子（BiTEs）的 CAR-T 细胞可规避抗原逃逸而无明显毒性。
Nat Biotechnol. 2019 Sep;37(9):1049-1058. doi: 10.1038/s41587-019-0192-1. Epub 2019 Jul 22.
3
A safe and potent anti-CD19 CAR T cell therapy.一种安全有效的抗 CD19 CAR T 细胞疗法。
应对感染性骨缺损的挑战：双功能生物材料的最新进展综述
J Nanobiotechnology. 2025 Mar 29;23(1):257. doi: 10.1186/s12951-025-03295-0.
4
Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR-T-Cell Therapy.解锁凋亡途径：克服 CAR-T 细胞疗法中的肿瘤耐药性。
Cancer Med. 2024 Oct;13(19):e70283. doi: 10.1002/cam4.70283.
5
Apoptosis, a Metabolic "Head-to-Head" between Tumor and T Cells: Implications for Immunotherapy.细胞凋亡，肿瘤与 T 细胞之间的代谢“正面交锋”：对免疫治疗的影响。
Cells. 2024 May 27;13(11):924. doi: 10.3390/cells13110924.
6
Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics.单独使用 CAR T 细胞和联合使用 BH3 模拟物时 Bcl-2 家族蛋白过表达的比较分析。
Sci Transl Med. 2024 Jun 5;16(750):eadk7640. doi: 10.1126/scitranslmed.adk7640.
7
ODF3B affects the proliferation and apoptosis of glioma via the JAK/STAT pathway.ODF3B通过JAK/STAT信号通路影响胶质瘤的增殖和凋亡。
Am J Cancer Res. 2024 Mar 15;14(3):1419-1432. doi: 10.62347/GHKF1995. eCollection 2024.
8
Exploring the apoptotic effects of sericin on HCT116 cells through comprehensive nanostring transcriptomics and proteomics analysis.通过全面的纳米串转录组学和蛋白质组学分析探索丝胶对 HCT116 细胞的凋亡作用。
Sci Rep. 2024 Jan 29;14(1):2366. doi: 10.1038/s41598-024-52789-8.
9
Delayed vaccine-induced CD8 T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication.拓扑异构酶 I 抑制作用延迟疫苗诱导的 CD8 T 细胞扩增，介导增强的 CD70 依赖性肿瘤清除。
J Immunother Cancer. 2023 Nov 29;11(11):e007158. doi: 10.1136/jitc-2023-007158.
10
Progressively Enhancing Stemness of Adoptively Transferred T Cells with PI3Kδ Blockade Improves Metabolism and Antitumor Immunity.PI3Kδ 阻断增强过继转移 T 细胞干性以改善代谢和抗肿瘤免疫。
Cancer Res. 2024 Jan 2;84(1):69-83. doi: 10.1158/0008-5472.CAN-23-0801.
Nat Med. 2019 Jun;25(6):947-953. doi: 10.1038/s41591-019-0421-7. Epub 2019 Apr 22.
4
Emerging Cellular Therapies for Cancer.新兴的癌症细胞疗法
Annu Rev Immunol. 2019 Apr 26;37:145-171. doi: 10.1146/annurev-immunol-042718-041407. Epub 2018 Dec 10.
5
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
6
Engineering CAR-T Cells for Improved Function Against Solid Tumors.工程化 CAR-T 细胞以改善对实体瘤的功能。
Front Immunol. 2018 Oct 29;9:2493. doi: 10.3389/fimmu.2018.02493. eCollection 2018.
7
Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.线粒体去乙酰化酶 SIRT3 在实验性同种异体造血移植后供体细胞反应中发挥重要作用。
J Immunol. 2018 Dec 1;201(11):3443-3455. doi: 10.4049/jimmunol.1800148. Epub 2018 Nov 2.
8
Molecular Approaches to Safe and Controlled Engineered T-cell Therapy.安全且可控的工程化T细胞疗法的分子方法
Acta Naturae. 2018 Apr-Jun;10(2):16-23.
9
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.CAR-T 细胞靶向递送 PD-1 阻断 scFv 增强体内抗肿瘤疗效。
Nat Biotechnol. 2018 Oct;36(9):847-856. doi: 10.1038/nbt.4195. Epub 2018 Aug 13.
10
The global landscape of cancer cell therapy.癌细胞治疗的全球格局。
Nat Rev Drug Discov. 2018 Jul;17(7):465-466. doi: 10.1038/nrd.2018.74. Epub 2018 May 25.